High Profit Margin Stocks in Health Care
Companies with profit margins above 15%, demonstrating efficient conversion of revenue into profit.
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
31 Companies Meeting Criteria
| # | Company | Profit Margin | Net Income | Revenue |
|---|---|---|---|---|
| 1 | HALOHalozyme | 47.9% | $595M | $1.2B |
| 2 | ADMAADMA Biologics, Inc. | 46.4% | $198M | $426M |
| 3 | PVLAPALVELLA THERAPEUTICS, INC. | 43.7% | $19M | $43M |
| 4 | UTHRUnited Therapeutics | 40.6% | $1.3B | $3.1B |
| 5 | RPRXRoyalty Pharma plc | 38.0% | $859M | $2.3B |
| 6 | CRONCronos Group Inc. | 34.9% | $41M | $118M |
| 7 | CPRXCatalyst Pharmaceuticals Partners, Inc. | 33.3% | $164M | $492M |
| 8 | REGNRegeneron Pharmaceuticals | 32.1% | $4.6B | $14.2B |
| 9 | VRTXVertex Pharmaceuticals | 31.4% | $3.7B | $11.7B |
| 10 | LLYLilly (Eli) | 31.0% | $18.4B | $59.4B |
| 11 | KRYSKrystal Biotech, Inc. | 30.7% | $89M | $291M |
| 12 | MRKMerck & Co. | 29.6% | $19.0B | $64.2B |
| 13 | EXELExelixis | 29.6% | $678M | $2.3B |
| 14 | ZTSZoetis | 28.2% | $2.7B | $9.4B |
| 15 | GILDGilead Sciences | 27.9% | $8.1B | $29.1B |
| 16 | JNJJohnson & Johnson | 27.3% | $25.1B | $92.1B |
| 17 | ACADAcadia Pharmaceuticals | 24.9% | $261M | $1.0B |
| 18 | INCYIncyte | 24.7% | $1.2B | $4.8B |
| 19 | CTMXCytomX Therapeutics, Inc. | 23.1% | $32M | $138M |
| 20 | ALKSAlkermes plc | 22.3% | $339M | $1.5B |
| 21 | AMPHAmphstar Pharmaceuticals, Inc. | 21.8% | $160M | $732M |
| 22 | CORTCorcept Therapeutics Incorporated | 20.9% | $141M | $675M |
| 23 | HRMYHarmony Biosciences Holdings, Inc. | 20.4% | $145M | $715M |
| 24 | AMGNAmgen | 19.5% | $7.0B | $36.0B |
| 25 | LGNDLigand Pharmaceuticals, Inc. | 19.3% | $49M | $251M |
| 26 | PBHPrestige Consumer Healthcare | 18.9% | $215M | $1.1B |
| 27 | GYREGYRE THERAPEUTICS, INC. | 16.9% | $18M | $106M |
| 28 | BMRNBioMarin Pharmaceutical | 16.8% | $520M | $3.1B |
| 29 | BIIBBiogen | 16.0% | $1.6B | $10.1B |
| 30 | NBIXNeurocrine Biosciences | 16.0% | $428M | $2.7B |
| 31 | PFEPfizer | 15.7% | $9.8B | $62.8B |
Understanding High Profit Margins
A profit margin above 15% indicates a company keeps more than 15 cents of every dollar earned as profit. This often reflects strong pricing power, a differentiated product, or efficient operations. Software and pharmaceutical companies tend to have the highest margins, while retailers and manufacturers typically operate on thinner margins.
Profit Margin > 15%
Results are based on SEC EDGAR filings. Companies with missing, unreliable, or extreme outlier values are excluded from screening.
Related Rankings
See the top companies ranked by these related metrics